Solasia Pharma K.K. (FRA:9SO)

Market Cap	40.21M -20.6%
Revenue (ttm)	1.88M +239.6%
Net Income	-10.34M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	0.1370
Previous Close	0.1370
Day's Range	0.1360 - 0.1370
52-Week Range	0.1320 - 0.2420
Beta	n/a
RSI	44.08
Earnings Date	Feb 13, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 23
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9SO

Financial Performance

In 2024, Solasia Pharma K.K.'s revenue was 316.00 million, a decrease of -48.78% compared to the previous year's 617.00 million. Losses were -1.94 billion, 74.6% more than in 2023.

Financial numbers in JPY